GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Moleculin Biotech Inc (FRA:MOL) » Definitions » Deferred Policy Acquisition Costs

Moleculin Biotech (FRA:MOL) Deferred Policy Acquisition Costs


View and export this data going back to 2016. Start your Free Trial

What is Moleculin Biotech Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Moleculin Biotech (FRA:MOL) Business Description

Industry
Traded in Other Exchanges
Address
5300 Memorial Drive, Suite 950, Houston, TX, USA, 77007
Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member.